de Braud, Filippo

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 1,244

Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort

Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., et al. (2020) · Journal of Thoracic Oncology

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 315

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions

Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 202

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Cassier, P. A., Dooms, C. A., Gazzah, A., Felip, E., Steeghs, N., Rohrberg, K. S., De Braud, F. G., Solomon, B. J., Schuler, M. H., Tan, D. S.-W., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 35